YTS105 / Peking University, BriSTAR Immunotech - LARVOL DELTA

The clinical outcomes of joint-preserving endoprosthesis reconstruction for primary sarcomas about the knee. (PubMed, J Orthop Surg Res) - "The joint-preserving endoprosthesis reconstruction (JPER) is a reliable technique to reconstruct massive bone defects after primary sarcoma resection about the knee with acceptable oncological outcomes, function, and satisfaction."

Clinical data • Journal • Ewing Sarcoma • Infectious Disease • Musculoskeletal Diseases • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • Spindle Cell Sarcoma • Undifferentiated Pleomorphic Sarcoma

PD-1 inhibitor in patients with minimal residual disease who failed donor lymphocyte infusion or interferon after allogeneic haematopoietic stem cell transplantation. (PubMed, Blood Cell Ther) - "Among these 6 patients, two received PD-1 alone while four received PD-1 plus azacitidine...Among the five evaluable patients, four achieved negative MRD with a median time to response of 2 months (range: 1-3 months); and the median duration of response was 105 days (range: 26-211 days). The median survival time of the five patients was 320 days (range: 107-350 days). Our data suggest that anti-PD-1 antibody in AML/MDS patients with positive MRD following allo-HSCT may be a treatment option."

Journal • Minimal residual disease • Acute Myelogenous Leukemia • Bone Marrow Transplantation • Hematological Malignancies • Leukemia • Myelodysplastic Syndrome • Oncology • Transplantation

Savolitinib (Savo) combined with osimertinib (osi) versus chemotherapy (chemo) in EGFR-mutant (EGFRm) and MET-amplification (METamp) advanced NSCLC after disease progression (PD) on EGFR tyrosine kinase inhibitor (TKI): Results from a randomized phase 3 SACHI study. (ASCO 2025) - P3 | "Eligible pts were randomly assigned (1:1) to receive savo 400 or 600 mg QD (for body weight of < 50, or ≥ 50 kg respectively) + osi 80 mg QD, or chemo (pemetrexed + carboplatin/cisplatin), stratified by brain metastases, prior use of 3G EGFR-TKI, and type of EGFR mutations... From 15 Oct 2021 to 30 Aug 2024 (DCO for IA), 211 pts were randomized to receive savo + osi or chemo (n=106 vs 105)... Savo + osi significantly improved PFS versus chemo in METamp NSCLC post EGFR-TKI, and the combination was safe and well tolerated. Savo + osi is a potential new treatment option for this genomically defined population. *52.4% of pts in chemo group were crossover to receive savo + osi or other MET Inhibitors."

Clinical • Late-breaking abstract • Metastases • P3 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR • MET

Performance Descriptor of Subsurface Metal-Promoted Boron Catalysts for Low-Temperature Propane Oxidative Dehydrogenation to Propylene. (PubMed, J Am Chem Soc) - "The metal-O binding energy, which has been demonstrated to be linearly correlated with H affinity, can serve as a straightforward performance descriptor for both low-temperature radical initialization and ODHP reaction, revealing this reaction is controlled by the Sabatier principle, and moderate metal-O binding energy is essential for achieving remarkable performance in the BOx/M/BN catalysts. Following the guidance of a potential descriptor, Ni-Rh alloy substrates are investigated and the substrate with a Ni/Rh molar ratio of 15:1 significantly enhances the low-temperature intrinsic activity of the metal-modified BOx to 9.26 μmol/(m2·s), which reaches 105.9 times that of h-BN and is 18.3% larger than the monometallic BOx/Ni/BN catalysts."

Journal

Robot-assisted radical nephroureterectomy using the KangDuo Surgical Robot-01 Sys-tem versus the da Vinci System: a multicenter prospective randomized controlled trial. (PubMed, Int Braz J Urol) - "The KD-SR-01 system is safe and effective for RARNU compared to the DV Si or Xi system. Further randomized controlled studies with larger sample sizes and longer durations are required."

Journal • Oncology

Immune checkpoint inhibitor-induced colitis with endoscopic evaluation in Chinese cancer patients: a single-centre retrospective study. (PubMed, Front Oncol) - "The median time from ICI initiation to colitis onset was 105 days...Twenty-three (92%) patients received steroids, and 3 (12%) added infliximab (IFX)...ICI rechallenge can achieve benefit, but permanently discontinuing ICIs is needed if colitis recurs. Future large-scale prospective studies are required for more accurate assessments and validation."

Checkpoint inhibition • Journal • Retrospective data • Gastroenterology • Gastrointestinal Disorder • Immunology • Oncology

EN BLOC RESECTION FOR SPINAL TUMORS: A SINGLE CENTER EXPERIENCE OF 113 CONSECUTIVE CASES (CTOS 2023) - "There were 29 recurrences, and the mean recurrence-free survival (RFS) was 105.8 (95% CI 87.5-124.1) months... Although en bloc resection for spinal tumors indicates complicated surgical procedure and high morbidity, it can significantly improve the OS of patients with primary malignant spinal tumors and the local control of primary malignant and aggressive spinal tumors. However, en bloc resection for spinal tumor showed no improvement in OS and local control in patients with solitary metastatic spinal tumor. It implies that further study should be focused on verifying whether metastatic tumor should be one of the indication of en bloc resections for spinal tumors or not."

Clinical • Oncology

Muricauda meishanensis sp. nov., a facultative anaerobic bacterium belonging to the family Flavobacteriaceae isolated from marine sediment in the East China Sea. (PubMed, Int J Syst Evol Microbiol) - "The 16S rRNA gene sequence analyses revealed that strain NBU2970 represents a novel species with the genus Muricauda, sharing highest sequence identities with Muricauda beolgyonensis BB-My12 (96.1 %), Muricauda alvinocaridis SCR12 (96.0 %), Muricauda taeanensis 105 (96.0 %) and Muricauda ruestringensis B1 (95.6 %)...is proposed. The type strain is NBU2970 (=KCTC 82915=MCCC 1K06394)."

Journal

Incidence of chronic obstructive pulmonary disease and risk factors in the Suzhou cohort (PubMed, Zhonghua Liu Xing Bing Xue Za Zhi) - "Participants were followed up for a median of 11.12 years, and 524 individuals were diagnosed with COPD during the follow-up period; the incidence was 105.54 per 100 000 person-years... The incidence of COPD is low in Suzhou. Older age, smoking, history of respiratory disease, and long sleep duration were risk factors for the development of COPD in the Suzhou cohort."

Journal • Cardiovascular • Chronic Obstructive Pulmonary Disease • Heart Failure • Immunology • Pulmonary Disease • Respiratory Diseases

PRELIMINARY PHASE 1B RESULTS OF ABSK021 FOR ADVANCED TENOSYNOVIAL GIANT CELL TUMOR: SIGNIFICANT ANTITUMOR ACTIVITY AND FAVOURABLE SAFETY PROFILE (CTOS 2022) - P1 | "The overall median treatment duration was 105 days (n=20, range: 49-164), and 96.3% (26/27) of the patients remained on treatment except one consent withdrawal, while 74.0% (20/27) of them have been on-treatment ≥3 months. ABSK021 has demonstrated significant antitumor activity and favourable safety profile with no apparent hepatotoxicity associated with CSF-1R inhibitors. This is the first result of an oral CSF-1R inhibitor with encouraging preliminary efficacy and safety results in Chinese advanced TGCT patients, which supports the further evaluation of ABSK021 as a promising treatment option for this disease."

Clinical • P1 data • Giant Cell Tumor of Bone • Hepatology • Immunology • Inflammation • Inflammatory Arthritis • Liver Failure • Oncology • Pain • Solid Tumor • Tenosynovial Giant Cell Tumor

MSLN STAR-T Cells in the Treatment of Advanced Malignant Solid Tumors (clinicaltrials.gov) - P1 | N=12 | Not yet recruiting | Sponsor: Peking University

New P1 trial • Cholangiocarcinoma • Lung Non-Squamous Non-Small Cell Cancer • Oncology • Solid Tumor • ALK • EGFR • MET • MSLN • ROS1